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Introduction {#sec1}
============

Balanced cellular metabolism is essential for cell survival and proliferation in embryogenesis and cancer biology. Metabolic balance is shifted when the cell fate is changed in somatic reprogramming or stem cell differentiation ([@bib10], [@bib45], [@bib48]). Increasing evidence shows that the modulation of cellular metabolism affects self-renewal and cell-fate determination ([@bib21], [@bib36], [@bib54]). Pyruvate is the keystone molecule in mammalian metabolism and has been widely used to culture human preimplantation embryos and human embryonic stem cells (hESCs) ([@bib4], [@bib12], [@bib20]). Here we investigated the impact of exogenous pyruvate on hESC metabolism, and further revealed its roles in signal transduction and cell-fate determination.

Pyruvate is the main product from glycolysis, and can be utilized in either lactate production or generation of acetyl-coenzyme A (CoA) for the tricarboxylic acid (TCA) cycle ([@bib15]). In pluripotent stem cells, pyruvate is mainly converted to lactic acid via lactic acid fermentation, and the rest is utilized through the TCA cycle to produce energy in oxidative phosphorylation ([@bib15], [@bib26], [@bib35]). In contrast, pyruvate is mainly metabolized through the TCA cycle in somatic cells ([@bib36]). The interference of pyruvate-related metabolism has a profound impact on autophagy, cell survival, and cell differentiation in stem cells ([@bib13], [@bib32], [@bib33]). For example, the inhibition of glycolysis suppresses endogenous pyruvate production and induces differentiation ([@bib3], [@bib27], [@bib32], [@bib49]). During gastrulation and stem cell differentiation, the balance of pyruvate usage is shifted from glycolysis to mitochondrial oxidative metabolism ([@bib4], [@bib12], [@bib20]). All the evidence suggests that pyruvate plays a central role in stem cell regulation.

Cells in our body are constantly under the influence of extracellular pyruvate, which can be imported through its transporters for intracellular metabolism ([@bib18], [@bib38]). Exogenous pyruvate has been widely used in clinical practice and basic research. In clinical practice, systemic administration of pyruvate is used as a therapeutic intervention for cardiac, neurological, and acid-base disorders ([@bib42]). In basic research, up to 40 mM pyruvate has been used in cell culture, and many basic culture media contain 0.5--1 mM pyruvate ([@bib8], [@bib19], [@bib51]). Pyruvate is used in all preimplantation embryo and hESC media ([@bib4], [@bib12], [@bib20]), and displays cellular protection to stem cells ([@bib14], [@bib19], [@bib39], [@bib42]). In our laboratory we use E8 medium, which contains 0.5 mM pyruvate, to maintain hESCs.

Exogenous pyruvate is important in early embryogenesis. Pyruvate uptake from media is essential for preimplantation embryos ([@bib4]). Pyruvate regulates the nuclear localization of TCA-cycle enzymes and is required for the genomic activation in mammalian zygote ([@bib33]). At the same time, pyruvate also plays a role in epigenetic modification. Pyruvate is converted to acetyl-CoA, which contributes to histone acetylation ([@bib32], [@bib37]). Elevated exogenous pyruvate also promotes the nuclear translocation of pyruvate dehydrogenase (PDH) for histone acetylation ([@bib46]). In addition, pyruvate generates α-ketoglutarate (α-KG) in the TCA cycle, which is involved in DNA methylation ([@bib7], [@bib32], [@bib47]). Given its essential roles in embryogenesis, it would be important to explore the regulatory functions of pyruvate in hESC maintenance and differentiation.

Pluripotency and differentiation are influenced by exogenous metabolites such as methionine, serine, acetate, and membrane-permeable α-KG analog (dimethyl α-KG, DM2OG) ([@bib7], [@bib23], [@bib33], [@bib44], [@bib50]). We and others have shown that some exogenous metabolites can also influence signaling cascades ([@bib30], [@bib6]). Because of pyruvate\'s critical roles in metabolism and early embryogenesis, we hypothesize that exogenous pyruvate can influence metabolism and signaling pathways in hESCs. In this report, we demonstrate that elevated exogenous pyruvate alters the metabolic profile and enhances oxidative metabolism. Pyruvate changes the expression of metabolic genes and the phosphorylation of metabolic enzymes. In differentiation, pyruvate potentiates mesodermal and endodermal lineage-specific differentiation. We further show that pyruvate stimulates mesoderm differentiation by modulating AMP kinase (AMPK) and mammalian target of rapamycin (mTOR) pathways. Our study highlights pyruvate as a key modulator that integrates metabolism and signal transduction in stem cell regulation.

Results {#sec2}
=======

Exogenous Pyruvate Shifts Metabolic Balance in Undifferentiated hESCs {#sec2.1}
---------------------------------------------------------------------

Considering pyruvate\'s central role in glycolysis and mitochondrial metabolism, we investigated how elevated exogenous pyruvate influences cellular activities in hESCs. To understand the interactions between different culture components, we chose chemically defined E8 medium as the platform to study pyruvate influence. All of the media contain 0.5 mM pyruvate in base medium, and extra pyruvate was added to test the impact of elevated exogenous pyruvate.

We first examined whether elevated exogenous pyruvate directly affects cellular metabolism in hESCs. Oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) were measured in H1 hESCs using extracellular metabolic flux analyses conducted by the Seahorse Analyzer. Elevated exogenous pyruvate significantly increased maximal respiration and spare respiration capacity in the cell Mito stress test ([Figures 1](#fig1){ref-type="fig"}A and 1B). At the same time, ECAR was suppressed by elevated pyruvate in the cell glycolysis stress test ([Figure 1](#fig1){ref-type="fig"}C). Elevated exogenous pyruvate significantly suppressed glycolytic capacity and glycolysis ([Figure 1](#fig1){ref-type="fig"}D). We also tested metabolic changes in fibroblast cells, whereby pyruvate showed no effect on OCR and ECAR levels ([Figures S1](#mmc1){ref-type="supplementary-material"}A and S1B).Figure 1Exogenous Pyruvate Alters Metabolic Balance in hESC Maintenance(A) Oxygen consumption rate (OCR) of H1 cells under different concentrations of pyruvate (Pyr), measured with Mito stress test. Pyruvate treatment was added during the assay (n ≥ 3 biological repeats).(B) Basal respiration, maximal respiration, and spare respiratory capacity of H1 cells, calculated from Mito stress test results in (A) (n = 3 biological repeats, ^∗^p \< 0.05; ns, not significant).(C) Extracellular acidification rate (ECAR) of H1 cells under different concentrations of pyruvate (Pyr), measured with glycolysis stress test. Pyruvate treatment was added during the assay (n ≥ 3 biological repeats).(D) Glycolytic capacity, glycolysis level, and glycolytic reserve of H1 cells, calculated from glycolysis stress test results in (B) (n = 3 biological repeats, ^∗^p \< 0.05; ns, not significant).(E) LC-MS analysis of intracellular pyruvate levels under exogenous pyruvate treatment. H1 cells were cultured with 16 mM pyruvate for 0, 3, 6, and 24 h in E8 medium before sample collection (n ≥ 3 biological repeats, ^∗^p \< 0.05).(F) Heatmap showing the intracellular levels of key metabolites in TCA cycle, glycolysis, and pentose phosphate (PPP) pathways under pyruvate treatment, measured by LC-MS. H1 cells were treated with 16 mM pyruvate for 3, 6, and 24 h. Metabolite levels at each time point were normalized to the levels in E8-cultured cells, and colors represent fold change.(G) Cytoscape network map with the Metscape plug-in generated from LC-MS data in (F), showing the relative fold changes of metabolites after 16 mM pyruvate treatment for 24 h. Red nodes indicate significantly increased metabolite levels compared with control (E8), blue nodes indicate significantly decreased levels, and gray nodes indicate no significant changes. The size of nodes represents relative fold changes (n ≥ 3 biological repeats).See also [Figure S1](#mmc1){ref-type="supplementary-material"}.

We then assessed pyruvate\'s effect on metabolism by liquid chromatography-mass spectrometry (LC-MS). As expected, elevated exogenous pyruvate significantly increased the intracellular pyruvate level ([Figure 1](#fig1){ref-type="fig"}E), indicating that pyruvate was imported into hESCs. Further analysis by LC-MS showed that pyruvate treatment significantly increased almost all metabolites in the TCA cycle except for acetyl-coA. Meanwhile, most metabolites in glycolysis and pentose pathway were not significantly changed besides glucose (Glc), sedoheptulose 7-phosphate (S7P), and lactic acid (Lac) ([Figures 1](#fig1){ref-type="fig"}F and 1G). The increased TCA-cycle metabolites and decreased lactic acid were consistent with the metabolism test by Seahorse Analyzer ([Figures 1](#fig1){ref-type="fig"}A--1D). These data indicate that exogenous pyruvate significantly promote mitochondrial oxidative phosphorylation for energy generation in hESCs.

Lineage-Specific Effects of Exogenous Pyruvate during Differentiation {#sec2.2}
---------------------------------------------------------------------

The shift of energy production from glycolysis to oxidative phosphorylation is often associated with the exit from self-renewal ([@bib5], [@bib16], [@bib45], [@bib53]). We examined whether the shifted metabolic balance by pyruvate could affect gene expression of pluripotency markers. Additional pyruvate did not significantly change the expression of *NANOG*, *POU5F1*, and *SOX2* in hESCs maintained in E8 medium ([Figure S1](#mmc1){ref-type="supplementary-material"}C).

We then examined whether pyruvate affects differentiation in different platforms ([Figure S1](#mmc1){ref-type="supplementary-material"}D). In spontaneous differentiation, the expression of *NANOG*, *POU5F1*, and *SOX2* decreased to a similar extent with or without extra pyruvate ([Figure S1](#mmc1){ref-type="supplementary-material"}E), but elevated pyruvate increased the expression of *TBXT* (*BRACHYURY*, *T*), *MIXL1*, *HHEX*, *EOMES*, and *SOX17* in mesoderm and endoderm lineages ([Figure S1](#mmc1){ref-type="supplementary-material"}F), while suppressing the expression of ectodermal markers *PAX6*, *PAX3*, and *SOX1* ([Figure S1](#mmc1){ref-type="supplementary-material"}G). This suggests that pyruvate has distinctive effects on the spontaneous differentiation to different lineages.

We further investigated the impact of exogenous pyruvate during lineage-specific differentiation, including mesoderm, endoderm, and ectoderm differentiation ([Figure S1](#mmc1){ref-type="supplementary-material"}D). Elevated pyruvate suppressed the expression of *PAX6* and *SOX1* in ectoderm differentiation under the dual inhibition of transforming growth factor β (TGFβ) and bone morphogenetic protein (BMP) pathways ([Figure S1](#mmc1){ref-type="supplementary-material"}H). In endoderm differentiation induced by activin A, endoderm marker *SOX17* expression was significantly increased by elevated pyruvate according to flow-cytometry analysis ([Figure S1](#mmc1){ref-type="supplementary-material"}I). In BMP4-driven mesoderm differentiation, elevated pyruvate significantly enhanced the expression of mesodermal markers *TBXT* and *MIXL1* ([Figure 2](#fig2){ref-type="fig"}A). These results suggest that elevated exogenous pyruvate affects hESC differentiation in a lineage-specific manner. In the rest of this study we focused on the molecular mechanisms of pyruvate in mesoderm differentiation.Figure 2Exogenous Pyruvate Potentiates Mesoderm Differentiation under BMP4 Induction through WNT Pathway(A) Effect of pyruvate on BMP4-induced mesoderm differentiation. H1 cells were induced to mesoderm cell fate by BMP4 in E8 medium with or without pyruvate supplement and collected on day 2 for qRT-PCR analysis (n = 3 independent experiments, ^∗^p \< 0.05).(B) Dose response to pyruvate during mesoderm differentiation. H1 cells were induced toward mesoderm cell fate by BMP4 in the presence of pyruvate at different concentrations, and the expression of *TBXT* and *MIXL1* was measured by qRT-PCR after 2 days. Data shown are normalized to day-0 levels (n = 3 independent experiments, ^∗^p \< 0.05).(C) FACS analysis of TBXT expression on day 3 of BMP4-induced differentiation with or without pyruvate treatment. Left: representative image of histogram. Right: bar graph showing mean ± SD of three independent experiments (^∗^p \< 0.05).(D) Immunostaining of TBXT on day 3 of BMP4-induced differentiation with or without pyruvate treatment. Control, no BMP4 treatment. Scale bars, 50 μm.(E) Microarray analysis of gene expression in major lineages after 2 days and 6 days of pyruvate treatment during H1 maintenance or mesoderm induction.(F) Time course of gene expression (*TBXT*/*MIXL1*) under pyruvate treatment during mesoderm differentiation, measured by qRT-PCR. Results are representative of three independent experiments.(G) qRT-PCR analysis of WNT pathway-related genes during BMP4-induced differentiation with or without 16 mM pyruvate treatment for 2 days (n = 3 independent experiments, ^∗^p \< 0.05).(H) Schematic showing pyruvate modulation of BMP4- and WNT pathway-induced mesoderm differentiation. CHIR99021 is an activator of WNT pathway, and IWP2 is an inhibitor of WNT pathway.(I) qRT-PCR analysis of the effect of WNT inhibitor IWP2 (3 μM) on mesoderm differentiation with or without pyruvate (Pyr) treatment for 2 days (n = 3 independent experiments, ^∗^p \< 0.05).(J) qRT-PCR analysis of the impact of pyruvate on 5 μM CHIR99021-induced mesoderm differentiation for 1 day (n = 3 independent experiments, not significant \[ns\]).See also [Figures S1](#mmc1){ref-type="supplementary-material"} and [S2](#mmc1){ref-type="supplementary-material"}.

Exogenous Pyruvate Potentiates Mesoderm Differentiation under BMP4 Induction {#sec2.3}
----------------------------------------------------------------------------

We further investigated how exogenous pyruvate affects mesoderm induction ([Figure 2](#fig2){ref-type="fig"}A). The expression of mesoderm markers *TBXT* and *MIXL1* were significantly elevated by pyruvate in a dose-dependent manner, and the maximum effect was reached at 16 mM pyruvate ([Figure 2](#fig2){ref-type="fig"}B). The effect of pyruvate on mesoderm differentiation was validated in multiple hESC and induced pluripotent stem cell (iPSC) lines, including H9 hESCs, and ND1 and ND2 human iPSCs ([Figure S1](#mmc1){ref-type="supplementary-material"}J). The positive impact by pyruvate was then confirmed by fluorescence-activated stem cell (FACS) analysis and immunostaining of *TBXT* expression in H1 cells ([Figures 2](#fig2){ref-type="fig"}C and 2D).

Global gene expression was evaluated with microarray analysis, and elevated pyruvate induced significant changes in gene expression during differentiation ([Figure S2](#mmc1){ref-type="supplementary-material"}A). Under BMP4 treatment, elevated pyruvate significantly increased mesendoderm gene expression after treatment for 2 days and 6 days ([Figure 2](#fig2){ref-type="fig"}E). Pyruvate led to a distinctive expression profile in glycolysis- and TCA-cycle-related genes ([Figures S2](#mmc1){ref-type="supplementary-material"}B and S2C). Interestingly, the pattern of metabolic gene expression was influenced by BMP4 treatment. Pyruvate also enhanced gene expression related to gastrulation and the development of various organs ([Figure S2](#mmc1){ref-type="supplementary-material"}D). We also showed that pyruvate positively affected gene expression in various aspects of cellular functions, such as metabolism, cell adhesion, extracellular matrix signaling, and Sonic Hedgehog and WNT pathways ([Figure S2](#mmc1){ref-type="supplementary-material"}E). These data were consistent with the modulation of metabolism and epithelial-to-mesenchymal transition during mesoderm differentiation.

To understand how the pyruvate effect is related to signal transduction, we examined the emergence of key mesodermal genes at specific time points. Elevated pyruvate not only enhanced *TBXT and MIXL1* expression but also accelerated their emergence ([Figure 2](#fig2){ref-type="fig"}F). This indicates that pyruvate sensitized the cellular response to BMP4 during mesoderm cell-fate determination. We then investigated whether the elevated pyruvate could bypass the requirement of key signaling pathways. Even with additional pyruvate, mesodermal differentiation was suppressed by the inhibitors of ERK, BMP, or TGFβ pathways ([Figure S2](#mmc1){ref-type="supplementary-material"}F), suggesting that pyruvate is not an active differentiation inducer but augments differentiation upon induction. This is also consistent with previous findings that the elevated pyruvate in E8 medium did not decrease pluripotency gene expression on its own ([Figure S1](#mmc1){ref-type="supplementary-material"}C).

WNT activation is a key event in mesodermal commitment in BMP4-induced mesoderm differentiation ([Figure 2](#fig2){ref-type="fig"}H) ([@bib24]). Under BMP4 treatment, pyruvate enhanced the expression of key WNT pathway genes including *WNT3*, *WNT3A*, *TWIST1*, and *SNAI1* ([Figure 2](#fig2){ref-type="fig"}G). Microarray data also showed increased gene expression in some components of the canonical WNT pathway ([Figure S2](#mmc1){ref-type="supplementary-material"}G). qPCR analysis showed that the expression pattern of WNT receptor family members was also affected by pyruvate, BMP4, and their joint treatments ([Figure S2](#mmc1){ref-type="supplementary-material"}H). The WNT inhibitor IWP2 significantly suppressed *TBXT* and *MIXL1* expression ([Figure 2](#fig2){ref-type="fig"}I). Interestingly, additional pyruvate did not enhance mesodermal differentiation that was initiated by WNT pathway activator CHIR99021 ([Figure 2](#fig2){ref-type="fig"}J). This indicates that the pyruvate effect is stage specific. Pyruvate promotes BMP4-induced differentiation, but WNT activation bypasses the need for elevated pyruvate.

Exogenous Pyruvate Increases Metabolism in the TCA Cycle during Mesoderm Differentiation {#sec2.4}
----------------------------------------------------------------------------------------

We examined whether mesoderm differentiation could be affected by the modulators of pyruvate-related metabolism ([Figure 3](#fig3){ref-type="fig"}A). We showed that the glycolysis inhibitor 2-deoxy-D-glucose (2-DG) significantly suppressed mesoderm marker gene expression induced by BMP4, and the addition of pyruvate partially rescued the phenotype ([Figure 3](#fig3){ref-type="fig"}B). In contrast, 2-DG did not have the same inhibitory effect on mesodermal differentiation induced by the WNT activator CHIR99021 ([Figure S3](#mmc1){ref-type="supplementary-material"}A). We also used UK5099 to inhibit pyruvate transportation across mitochondrial membrane ([@bib28]). UK5099 significantly inhibited mesodermal induction, but elevated exogenous pyruvate fully rescued the differentiation phenotype ([Figure 3](#fig3){ref-type="fig"}C). At the same time, mesoderm differentiation is not affected by the inhibition of lactic acidosis by FX11, a lactate dehydrogenase A (LDHA) inhibitor ([Figure S3](#mmc1){ref-type="supplementary-material"}B). These results suggest that pyruvate production and its mitochondrial metabolism are important for mesodermal induction.Figure 3Exogenous Pyruvate Modulates TCA-Cycle Activity in Maintenance and Mesoderm Differentiation(A) Schematic showing the glycolysis pathway and the functions of relevant inhibitors.(B) qRT-PCR analysis of the impact of 3 mM 2-DG during BMP4-induced differentiation with or without 16 mM pyruvate treatment for 2 days (n = 3 independent experiments, ^∗^p \< 0.05).(C) qRT-PCR analysis of the impact of 3 μM UK5099 during BMP4-induced differentiation with or without 16 mM pyruvate treatment for 2 days (n = 3 independent experiments, ^∗^p \< 0.05; ns, not significant).(D) Schematic of pyruvate dehydrogenase (PDH) and the function of pyruvate and PDK inhibitor DCA.(E) Western blotting analysis of PDHE1α phosphorylation during maintenance and differentiation, with or without 8 or 16 mM pyruvate treatment. Results shown are representative of three independent experiments.(F) qRT-PCR analysis of the impact of 3 mM DCA during BMP4-induced differentiation with or without 16 mM pyruvate treatment for 2 days (n = 3 independent experiments, ^∗^p \< 0.05; ns, not significant).(G) Levels of key metabolites during maintenance and differentiation, measured by LC-MS analysis. H1 cells were cultured with or without 16 mM pyruvate for 24 h with or without BMP4 induction in E8 medium. Metabolite levels were normalized to the levels in control cells without BMP4 or pyruvate treatment (n = 3 biological repeats, ^∗^p \< 0.05).(H) Effects of metabolites on early mesoderm differentiation. Pyr, sodium pyruvate; α-KG, dimethyl 2-oxoglutarate; Suc, dimethyl succinate (n = 3 independent experiments, ^∗^p \< 0.05; ns, not significant compared with control). None, no pyruvate treatment.See also [Figure S3](#mmc1){ref-type="supplementary-material"}.

After pyruvate is imported into mitochondria, it is converted to acetyl-CoA for the TCA cycle by the pyruvate dehydrogenase (PDH) complex. Phosphorylation of PDHE1α by pyruvate dehydrogenase kinase (PDK) leads to PDH inhibition and TCA-cycle suppression ([Figure 3](#fig3){ref-type="fig"}D). We showed that elevated pyruvate suppressed PDHE1α phosphorylation in a dose-dependent manner both in E8 medium and under BMP4-containing differentiation conditions ([Figures 3](#fig3){ref-type="fig"}E and [S3](#mmc1){ref-type="supplementary-material"}C). This indicates that exogenous pyruvate induces a feedback to promote its own metabolism and generate more acetyl-CoA by suppressing PDH phosphorylation. The PDK inhibitor dichloroacetate (DCA) suppresses PDH phosphorylation and promotes pyruvate conversion to acetyl-CoA ([@bib40], [@bib41], [@bib43]). It was also reported that DCA suppresses pluripotency by promoting the PDH cycle ([@bib40]). We showed that DCA significantly enhanced mesodermal differentiation ([Figure 3](#fig3){ref-type="fig"}F). Taken together, these results suggest that increased pyruvate metabolism in mitochondria is beneficial to mesodermal differentiation.

To understand how pyruvate metabolism through the TCA cycle could affect differentiation, we examined the metabolite profile 24 h after pyruvate treatment in either maintenance or differentiation conditions. In both conditions, exogenous pyruvate treatment significantly increased the intracellular levels of TCA-cycle metabolites, including citrate, α-ketoglutarate, succinate, fumarate, malate, and oxaloacetate ([Figure 3](#fig3){ref-type="fig"}G). We then inspected whether the metabolites in the TCA cycle could affect mesoderm differentiation. Dimethyl α-KG (α-KG) and dimethyl succinate (Suc) did not significantly enhance mesoderm differentiation as strongly as pyruvate, and caused cell death at high concentration ([Figure 3](#fig3){ref-type="fig"}H), implying that pyruvate does not regulate differentiation through its TCA-cycle metabolites. Researchers also reported that histone acetylation influences hESC differentiation ([@bib32]). We used acetate and butyrate to promote histone acetylation, and also applied anacardic acid to inhibit histone acetylation. We found that none of them enhanced mesoderm differentiation, similar to pyruvate ([Figure S3](#mmc1){ref-type="supplementary-material"}D). These data indicate that histone acetylation is not the main pathway that is activated by pyruvate in mesoderm differentiation.

Exogenous Pyruvate Increases AMP/ATP Ratio and Activates AMPK Pathway in Mesoderm Differentiation {#sec2.5}
-------------------------------------------------------------------------------------------------

While exploring pyruvate\'s impact on differentiation, we noticed that mesoderm differentiation was enhanced by pretreatment with exogenous pyruvate prior to BMP4 exposure ([Figure 4](#fig4){ref-type="fig"}A). This suggests that the elevated pyruvate leads to a long-lasting effect that allows the cells to respond to BMP4 more strongly. Microarray analysis showed that exogenous pyruvate promoted the expression of carbohydrate and lipid metabolism in maintenance E8 medium ([Figure S4](#mmc1){ref-type="supplementary-material"}A). Some genes related to signaling pathways were also upregulated, even though the cells did not differentiate ([Figure S4](#mmc1){ref-type="supplementary-material"}B). This suggests that pyruvate may lead to a feedback control signal that regulates metabolism, with long-term implications.Figure 4Exogenous Pyruvate Increases AMP/ATP Ratio and Activates the AMPK Pathway in Mesoderm Differentiation(A) Effect of pyruvate pretreatment on *TBXT*/*MIXL1* expression. hESCs were pretreated with 16 mM pyruvate in E8 medium for 24 h (day −1 to day 0) before the induction to mesoderm by BMP4 for 2 days (day 0 to day 2). *TBXT* and *MIXL1* expression were analyzed by qRT-PCR on day 2 (n = 3 independent experiments, ^∗^p \< 0.05).(B) LC-MS analysis of intercellular ATP, AMP, and AMP/ATP ratio under pyruvate treatment. H1 cells were cultured with 16 mM pyruvate for 0, 3, 6, and 24 h in E8 medium. Metabolite levels were normalized to the levels in control cells without pyruvate treatment (n ≥ 3 biological repeats, ^∗^p \< 0.05).(C) Western blotting analysis of pyruvate (8 or 16 mM) effects on AMPK phosphorylation. H1 cells were subjected to pyruvate treatment for 24 h during maintenance (E8) or differentiation (BMP4). Results shown are representative of three independent experiments.(D and E) Effect of AMPK activators during BMP4-induced differentiation with (E) or without (D) 16 mM pyruvate treatment for 2 days. AICAR, 1 mM; A769662, 10 μM (n = 3 independent experiments, ^∗^p \< 0.05; ns, not significant).(F) Western blotting analysis of pyruvate effects on mTOR pathway. H1 cells were treated with pyruvate (8 or 16 mM) for 24 h both in E8 and in BMP4-induced differentiation. AMPK activators (A769662, 10 μM and AICAR, 1 mM) and mTOR inhibitor (rapamycin, 50 nM) were added during BMP4-induced differentiation for 24 h. Results shown are representative of three independent experiments.(G) qRT-PCR analysis of the effect of mTOR pathway inhibitors during BMP4-induced differentiation for 2 days. Rapamycin, 50 nM (n = 3 independent experiments, ^∗^p \< 0.05; ns, not significant).(H) Proposed model of pyruvate action. mTOR is a central regulator of mesoderm differentiation, and pyruvate enhances differentiation by suppression of mTOR through AMPK.See also [Figure S4](#mmc1){ref-type="supplementary-material"}.

Considering pyruvate\'s role in metabolism, we conducted additional LC-MS analysis on cellular metabolites in hESCs ([Figure S4](#mmc1){ref-type="supplementary-material"}C). We noticed that pyruvate treatment increased the AMP level, and consequently elevated the AMP/ATP ratio after 3--24 h of treatment ([Figure 4](#fig4){ref-type="fig"}B). We showed that elevated pyruvate increased AMPK phosphorylation in a dose-dependent manner in both maintenance and differentiation conditions ([Figure 4](#fig4){ref-type="fig"}C). These data suggest that elevated pyruvate activates the AMPK pathway in hESCs.

Next, we examined whether AMPK activation could affect mesoderm differentiation. AMPK activators AICAR and A769662 significantly increased mesodermal differentiation under BMP4 induction ([Figure 4](#fig4){ref-type="fig"}D). At the same time, AMPK activators did not significantly increase mesodermal differentiation in the presence of elevated pyruvate, suggesting that they work in the same pathway ([Figure 4](#fig4){ref-type="fig"}E). We also found that the AMPK inhibitor Compound C inhibited *TBXT*/*MIXL1* expression regardless of pyruvate treatment ([Figure S4](#mmc1){ref-type="supplementary-material"}D). These data suggest that mesoderm differentiation is enhanced by AMPK activated by pyruvate treatment.

Finally, we analyzed whether AMPK\'s downstream effectors are involved in mesoderm differentiation ([Figure 4](#fig4){ref-type="fig"}F). AMPK suppresses the mTOR pathway ([@bib17]), so we examined the pyruvate impact on mTOR signaling. We showed that the phosphorylation of the mTOR regulator Raptor (S792) was significantly suppressed by pyruvate and AMPK activators, implying that the mTOR pathway was inhibited by pyruvate-AMPK through Raptor. At the same time, the phosphorylation of mTOR substrate p70S6K (T389) was also suppressed by pyruvate and AMPK activators, confirming that mTOR was inhibited by pyruvate and AMPK activators. These data suggest that pyruvate suppressed mTOR activity through AMPK in hESCs. We then examined whether mTOR inhibition could play a role in mesoderm differentiation. We found that the mTOR inhibitor rapamycin significantly increased mesodermal gene expression, and pyruvate did not provide an additive effect to enhance the differentiation ([Figures 4](#fig4){ref-type="fig"}G and [S4](#mmc1){ref-type="supplementary-material"}E). These results are consistent with previous reports that mTOR inhibition promotes mesoderm cell fate in hESCs ([@bib55], [@bib22], [@bib34], [@bib29]), and implies that pyruvate probably works in the same pathway as rapamycin in promoting mesoderm cell fate. Taken together, our data suggest that elevated exogenous pyruvate potentiates mesoderm differentiation through AMPK activation and mTOR inhibition ([Figure 4](#fig4){ref-type="fig"}H).

We further explored how elevated pyruvate could be used in hESC applications. We used BMP4 treatment to initiate mesoderm differentiation and then directed cell fate toward cardiomyocytes through WNT inhibition and heparin ([@bib25]). We found that BMP4 alone was inefficient for cardiomyocyte induction, while cardiomyocyte differentiation was significantly improved when pyruvate was applied during BMP4 induction ([Figures S4](#mmc1){ref-type="supplementary-material"}F and S4G). Pyruvate probably improves cardiac differentiation through enhanced WNT expression and mesoderm induction, which allows more efficient cardiomyocyte differentiation at a later stage. We believe that pyruvate can potentially be utilized in other lineage-specific differentiation methods in the near future.

Discussion {#sec3}
==========

Pyruvate is a keystone metabolite and its associated metabolism has long been implicated in embryogenesis and carcinogenesis, but it has not been considered as a modulator of differentiation or signal transduction. This study reveals that elevated exogenous pyruvate shifts metabolic balance, regulates kinase cascades, and profoundly affects lineage-specific differentiation in hESCs.

Metabolic balance is associated with pluripotency and differentiation ([@bib45], [@bib21]). In comparison with hESCs, mesoderm cells have differential gene expression and demonstrate increased oxidative phosphorylation ([@bib32]). We found that pyruvate metabolism not only was essential for mesoderm induction, but also shifted hESC metabolism quickly in a matter of hours. We think that in regular BMP4-initiated differentiation, metabolic balance shift follows the induction of cell differentiation and subsequently reinforces cell differentiation. Such a process requires multiple steps and requires a couple of days to execute. The elevation of oxidative phosphorylation by pyruvate allows the cells to respond to BMP4 more quickly and strongly, which leads to accelerated mesodermal differentiation ([Figure 2](#fig2){ref-type="fig"}F). Pyruvate accelerated WNT gene expression ([Figure 2](#fig2){ref-type="fig"}G) and altered the expression pattern of WNT receptors ([Figures S2](#mmc1){ref-type="supplementary-material"}G and S2H), both of which probably contributed to enhanced mesoderm differentiation. When the WNT pathway is directly activated by CHIR99021, cells are not as responsive to 2-DG and pyruvate as in BMP4-induced differentiation ([Figures 2](#fig2){ref-type="fig"}J and [S3](#mmc1){ref-type="supplementary-material"}A). We further showed that elevated pyruvate induces mesendoderm differentiation through inhibition of the mTOR pathway, which is consistent with previous reports that mTOR inhibitor enhances mesendoderm differentiation through lineage-specific metabolic flux ([@bib11], [@bib34], [@bib55]). We also noticed that pyruvate altered metabolic gene expression differentially depending on whether BMP4 was present. These data indicate that the effect of pyruvate is dependent on cell signaling, which could be caused either by the combinatory effect of metabolism and signal transduction or by cell-type-specific responses due to BMP4-induced differentiation. It would be interesting to further explore how metabolism and cell signaling pathways interact to coordinate cell-fate decisions.

With elevated concentration, metabolites such as nicotinamide can play regulatory roles not only in metabolism but also in signal transduction, and we explored whether pyruvate has similar effects in signaling pathways ([@bib30]). Exogenous pyruvate has been implicated in many cellular processes, but most studies focus on its role in metabolism and reactive oxygen species suppression ([@bib15], [@bib19], [@bib39], [@bib51]). Here we show that pyruvate modulates kinase cascades in signal transduction. This affects the phosphorylation status of multiple crucial proteins, such as PDHE1α and AMPK. We further demonstrate that pyruvate potentiates BMP4-induced differentiation through AMPK activation and mTOR inhibition. Based on the findings in this report, we propose that regulation of signaling pathways could be an important function of pyruvate. It would be interesting to re-examine the cellular events influenced by pyruvate to find out whether the control of signal transduction events is involved as potential underlying mechanisms.

Cell fate can be affected through epigenetic modifications by metabolites, such as acetate and α-KG ([@bib1], [@bib7], [@bib31], [@bib32], [@bib37], [@bib47]). We tested whether pyruvate promoted differentiation through epigenetic modulation. To our surprise, pyruvate demonstrated a much stronger effect on mesoderm differentiation, and neither acetate nor dimethyl α-KG affected differentiation in the same way as pyruvate ([Figures 3](#fig3){ref-type="fig"}H and [S3](#mmc1){ref-type="supplementary-material"}D). If pyruvate promoted mesoderm differentiation by enhancing histone acetylation similarly to other metabolites, we expected to see other activators of the process enhance mesoderm differentiation in a similar manner. However, our data showed that acetate, histone deacetylase (HDAC) inhibitor butyrate, and histone acetyltransferase (HAT) inhibitor showed no significant effect ([Figure S3](#mmc1){ref-type="supplementary-material"}D). This suggests that pyruvate did not exert its function on mesoderm differentiation mainly through histone acetylation. These data also demonstrate that metabolites in the same metabolic pathways may have differential impact on differentiation through different mechanisms. It would be interesting to know how epigenetic modification could be differentially affected by these nutrients.

In this report, we also demonstrate that pyruvate is an efficient tool for regulation of cellular function. Exogenous pyruvate is efficiently imported intracellularly to influence metabolism and signal transduction in embryos and stem cells. In comparison with pyruvate, other metabolites, such as α-KG and succinate, have to be chemically modified to increase their membrane permeability, and they also led to cell death at high concentrations ([Figure 3](#fig3){ref-type="fig"}H). In contrast, pyruvate is easy to access and can be used at high concentration for routine research and stem cell applications. As an example, we show that the potentiated differentiation by pyruvate could be used to improve cardiomyocyte differentiation. Pyruvate-treated cells gave rise to a significantly higher yield of cardiomyocytes in BMP4-initiated cardiac differentiation ([Figures S4](#mmc1){ref-type="supplementary-material"}F and S4G). Considering its unique characteristics in hESC regulation, pyruvate will be a useful tool to modulate metabolism and improve stem cell lineage-specific differentiation and other applications.

Experimental Procedures {#sec4}
=======================

Key Resources Table {#sec4.1}
-------------------

The key resources table is available in [Supplemental Information](#mmc1){ref-type="supplementary-material"}.

Contact for Reagent and Resource Sharing {#sec4.2}
----------------------------------------

Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, G.C. (<guokaichen@umac.mo>).

Experimental Model and Subject Details {#sec4.3}
--------------------------------------

### Human iPSC Lines {#sec4.3.1}

hESC lines (H1, H9) and human iPSC lines (ND1, ND2) were used in this study. A SOX17-GFP H9 cell line was used for endoderm differentiation ([@bib52]). The use of hESCs and hiPSCs was approved by the Institutional Review Board at the University of Macau.

### hESC Culture Maintenance and Passaging {#sec4.3.2}

Cells were maintained in home-made E8 medium (DMEM/F12, L-ascorbic acid, selenium, transferrin, insulin, fibroblast growth factor 2 \[FGF2\], and TGFβ) following published protocols ([@bib9]). In brief, cells were cultured in E8 medium (with 1× penicillin/streptomycin) on Matrigel-coated (Corning, 354230) plates. Confluent (∼80%) cells were passaged every 3--4 days using the DPBS-EDTA method as described by [@bib2]. ROCK inhibitor Y-27632 (5 μM) was used during cell passaging.

Unless otherwise stated, all the pyruvate concentrations in the article refer to the amount of pyruvate added to the medium (surplus to the 0.5 mM pyruvate in E8 medium).

### Spontaneous Differentiation {#sec4.3.3}

Spontaneous differentiation was conducted on the monolayer platform. Confluent (30%--50%) cells were cultured in E6 medium (E8 components minus FGF2 and TGFβ) with 1× penicillin/streptomycin for 12 days in the presence or absence of 8 mM pyruvate. Medium was changed every day. Expression of pluripotency and lineage-specific marker genes (*NANOG*, *POU5F1*, *SOX2*, *TBXT*, *MIXL1*, *SOX17*, *PAX6*) were tested via qRT-PCR.

### Mesoderm Differentiation {#sec4.3.4}

hESCs were differentiated under 20 ng/mL BMP4 (R&D Systems, 314-BP) induction in E8 medium for 2 days (or as specified in time-course experiments) with or without 16 mM pyruvate. Medium was changed every day. Expression of *T*/*MIXL1* was tested via qRT-PCR.

### Endoderm Differentiation {#sec4.3.5}

A SOX17-GFP H9 cell line was used for endoderm differentiation ([@bib52]). After differentiation induction by CHIR99021 (5 μM) for 1 day, hESCs were treated with 10 ng/mL activin A (R&D Systems, 338-AC) for 3 days in differentiation medium (E8 medium minus FGF2, TGFβ, and insulin). Pyruvate (16 mM) was added during activin A treatment. Medium was changed every day. Expression of SOX17-GFP was examined using an Accuri C6 flow cytometer.

### Ectoderm Differentiation {#sec4.3.6}

Cells were treated with 10 μM SB431542 (Selleck, S1067) + 100 nM LDN193189 (Selleck, S2618) for 4 days in E6 medium with or without 16 mM pyruvate. Medium was changed every day. Expression of *PAX6* were tested via qRT-PCR.

### Cardiac Differentiation {#sec4.3.7}

Cardiac differentiation from hESCs was carried out following published protocols ([@bib30]). Expression of *TNNT2*/*NKX2-5* was tested via qRT-PCR.

Method Details {#sec4.4}
--------------

Method details are available in [Supplemental Information](#mmc1){ref-type="supplementary-material"}.

Statistical Analysis {#sec4.5}
--------------------

Seahorse data and LC-MS data are presented as mean ± SD of three or more biological repeats. All other data are presented as mean ± SD of three independent experiments unless otherwise specified. Student\'s t test was used for statistical analysis, and p \< 0.05 was considered statistically significant.
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